Mario Scartozzi

Summary

Publications

  1. ncbi request reprint Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer
    Mario Scartozzi
    AO Ospedali Riuniti Università Politecnica delle Marche, Clinica di Oncologia Medica, Via Conca, 60020, Ancona, Italy
    Curr Opin Mol Ther 12:361-71. 2010
  2. pmc Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
    J Exp Clin Cancer Res 29:164. 2010
  3. pmc Clinical evidence for three distinct gastric cancer subtypes: time for a new approach
    Alessandro Bittoni
    Clinica di Oncologia Medica, AOU Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    PLoS ONE 8:e78544. 2013
  4. pmc Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    PLoS ONE 7:e38192. 2012
  5. doi request reprint Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey
    Mario Scartozzi
    Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona Università Politecnica delle Marche, Departments of Medical Oncology, Translational Research Unit, Via Conca, 60020, Ancona, Italy 39 071 5963834 39 071 5964192
    Expert Opin Pharmacother 15:143-50. 2014
  6. pmc VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
    M Scartozzi
    Department of Clinical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy
    Br J Cancer 108:1126-32. 2013
  7. pmc The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management
    Mario Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I Lancisi Salesi, Universita Politecnica delle Marche, Ancona, Italy
    PLoS ONE 7:e32653. 2012
  8. pmc Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Marche Via Conca, Ancona, 60020, Italy
    J Transl Med 10:71. 2012
  9. doi request reprint 5-Fluorouracil pharmacogenomics: still rocking after all these years?
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Ancona, Italy
    Pharmacogenomics 12:251-65. 2011
  10. doi request reprint The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
    Dig Liver Dis 43:194-8. 2011

Collaborators

Detail Information

Publications57

  1. ncbi request reprint Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer
    Mario Scartozzi
    AO Ospedali Riuniti Università Politecnica delle Marche, Clinica di Oncologia Medica, Via Conca, 60020, Ancona, Italy
    Curr Opin Mol Ther 12:361-71. 2010
    ..Although preliminary results appear promising, only future clinical and translational data will clarify the best clinical setting and treatment combinations for the optimal use of dalotuzumab in clinical practice...
  2. pmc Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
    J Exp Clin Cancer Res 29:164. 2010
    ..In our experience, lipiodol TACE showed a better OS and TTP over pTACE, without difference in toxicity profile and RR. Among the staging systems analyzed only the Okuda stage seemed able to reliably predict patients outcome...
  3. pmc Clinical evidence for three distinct gastric cancer subtypes: time for a new approach
    Alessandro Bittoni
    Clinica di Oncologia Medica, AOU Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    PLoS ONE 8:e78544. 2013
    ..Aim of our analysis was to compare clinical outcome according to different GC subtypes (1,2,3) in metastatic GC patients receiving first-line chemotherapy...
  4. pmc Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    PLoS ONE 7:e38192. 2012
    ..The selection tool deriving from this analysis may allow an optimal use of the available treatment strategies in these patients...
  5. doi request reprint Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey
    Mario Scartozzi
    Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona Università Politecnica delle Marche, Departments of Medical Oncology, Translational Research Unit, Via Conca, 60020, Ancona, Italy 39 071 5963834 39 071 5964192
    Expert Opin Pharmacother 15:143-50. 2014
    ..In the GI tumors area, key findings from the American Society of Clinical Oncology 2013 annual meeting were long awaited, particularly in colorectal, gastric and pancreatic cancer...
  6. pmc VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
    M Scartozzi
    Department of Clinical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy
    Br J Cancer 108:1126-32. 2013
    ..We assessed the role of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) polymorphisms in the prediction of the clinical outcome in metastatic renal cell carcinoma (mRCC) patients...
  7. pmc The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management
    Mario Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I Lancisi Salesi, Universita Politecnica delle Marche, Ancona, Italy
    PLoS ONE 7:e32653. 2012
    ....
  8. pmc Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Marche Via Conca, Ancona, 60020, Italy
    J Transl Med 10:71. 2012
    ..The EGFR pathway activation via the Ras-Raf-MAP-kinase and the protein-serine/threonine kinase AKT could determine resistance to anti-EGFR treatment...
  9. doi request reprint 5-Fluorouracil pharmacogenomics: still rocking after all these years?
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Ancona, Italy
    Pharmacogenomics 12:251-65. 2011
    ..In this article, we will focus on the often contradictory results of these studies...
  10. doi request reprint The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
    Dig Liver Dis 43:194-8. 2011
    ..The benefit of preoperative chemotherapy in patients with initially resectable liver metastases from colorectal cancer is still a matter of debate...
  11. doi request reprint Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 71, Ancona, 60020, Italy
    Curr Oncol Rep 12:175-85. 2010
    ..Along with new effective therapeutic opportunities, better clinical and molecularly driven patient selection will represent the cornerstone of the global care for these patients...
  12. doi request reprint Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 6020 Ancona, Italy
    Lung Cancer 68:433-7. 2010
    ....
  13. ncbi request reprint Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Ancona, Italy
    Cancer Treat Rev 35:451-62. 2009
    ..This systematic review will analyse available data about these factors with the aim to constitute a starting point for future research...
  14. ncbi request reprint State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti, Ancona, Italy
    Discov Med 11:144-53. 2011
    ..The efficacy profile seems to be promising. However, further studies are needed to define the exact role of IGF-1R inhibitors in clinical practice...
  15. doi request reprint Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan
    Mario Scartozzi
    Department of Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    Int J Cancer 127:1941-7. 2010
    ..Combined IGF-1 and K-RAS analysis may represent an effective strategy for a better selection of responding colorectal cancer patients...
  16. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009
    ..Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab...
  17. doi request reprint Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1
    Rossana Berardi
    Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Medical Oncology Unit, Ancona, Italy
    Expert Opin Pharmacother 10:2245-58. 2009
    ..This review discusses the role of neoadjuvant chemoradiotherapy regimens used in the standard combined modality treatment programs for rectal cancer and focuses on the ongoing research to improve these regimens...
  18. ncbi request reprint Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients
    Mario Scartozzi
    Department of Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    Pharmacogenomics 14:1991-8. 2013
    ..We examined the role of tumor angiogenesis genotyping in determining clinical outcome in metastatic gastric cancer patients receiving first-line chemotherapy...
  19. doi request reprint Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review
    Rossana Berardi
    Clinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Italy
    Crit Rev Oncol Hematol 69:223-36. 2009
    ..We extensively reviewed the published scientific literature on this topic in order to investigate the clinical and genetic profiling underlying lung cancer in women and to use this information as a tool for medical therapy...
  20. doi request reprint Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
    Stefano Cascinu
    Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
    Cancer Chemother Pharmacol 68:37-43. 2011
    ..With the aim to maintain efficacy while reducing toxicity, we compared the activity and safety of a combination of 5-FU, cisplatin and pegylated liposomal doxorubicin with a combination of 5-FU, cisplatin and mitomycin-C...
  21. doi request reprint Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice
    Mirco Pistelli
    Scuola di Specializzazione in Oncologia, Universita Politecnica delle Marche, Ancona, Italy
    Tumori 97:275-9. 2011
    ..We retrospectively evaluated the efficacy of FOLFIRI as second-line treatment in advanced gastric cancer patients progressing after platinum-based chemotherapy...
  22. ncbi request reprint COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin
    Stefano Cascinu
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda ospedaliera Ospedali Riuniti Umberto I, Lancisi, Salesi, Ancona, Italy
    Am J Clin Oncol 30:526-30. 2007
    ..We investigated the role of COX-2 and NF-KB expression in relation to the use of a COX-2 inhibitor (celecoxib) associated to gemcitabine and oxaliplatin in pancreatic cancer...
  23. doi request reprint Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2
    Rossana Berardi
    Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi G Salesi di Ancona, Medical Oncology Unit, 60020 Ancona, Italy
    Expert Opin Pharmacother 10:2467-78. 2009
    ..The present review analyzes the new molecular targets that could be involved in predicting response and prognosis...
  24. ncbi request reprint Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation
    Riccardo Giampieri
    Clinica di Oncologia Medica, AOU Ospedali Riuniti Università Politecnica delle Marche, Via Conca 71, Torrette, 60020 Ancona, Italy Electronic address
    Crit Rev Oncol Hematol 88:272-83. 2013
    ..This kind of approach leaves other, less known but by no means less important, putative mechanisms of resistance. We tried to shed some light on these mechanisms of resistance...
  25. ncbi request reprint Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy
    Mario Scartozzi
    Clinica di Oncologia Medica and Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
    J Clin Oncol 25:3930-5. 2007
    ..The aim of our analysis was to investigate a correlation between NF-kB expression, response rate, time to progression, and survival in advanced colorectal cancer patients receiving cetuximab and irinotecan...
  26. doi request reprint Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients
    Mario Scartozzi
    Clinica di Oncologia, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    Dig Liver Dis 44:74-9. 2012
    ..Retrospective analyses suggested that a pharmacogenetic approach may allow a tailored selection of chemotherapy for metastatic colorectal cancer...
  27. ncbi request reprint Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies
    Mario Scartozzi
    Clinica di Oncologia Medica, Istituto di Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
    J Clin Oncol 22:4772-8. 2004
    ....
  28. pmc The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
    Oncologist 16:53-60. 2011
    ..Combined HER-3 and K-RAS analysis may represent an effective strategy for better selection of responding colorectal cancer patients...
  29. ncbi request reprint Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer
    Mario Scartozzi
    Department of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti Università Politecnica delle Marche, Ancona and Istituto di Anatomia Patologica, Universita Politecnica delle Marche, Ancona, Italy
    Anal Quant Cytol Histol 28:61-8. 2006
    ..Moreover, the biological selection of colorectal tumors more likely to benefit from this treatment approach is still to be defined...
  30. doi request reprint Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    Future Oncol 9:1207-14. 2013
    ..The current study aimed to evaluate the interaction between polymorphisms of α6 and β4 integrins and clinical outcome in HER-3-negative, K-RAS wild-type colorectal cancer patients receiving cetuximab...
  31. ncbi request reprint Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients
    Mario Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti e Università Politecnica delle Marche, Ancona, Italy
    Lung Cancer 53:103-9. 2006
    ..031) and 10 months versus 9 months for hMSH2 (p=0.8330). Both the difference in response rate and in median survival observed according to MMR status seem to confirm what has been suggested by preclinical studies...
  32. doi request reprint Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome
    Rossana Berardi
    Medical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Ancona, Italy
    Int J Radiat Oncol Biol Phys 75:1437-43. 2009
    ..To determine the importance of downstaging of locally advanced rectal cancer after neoadjuvant treatment...
  33. doi request reprint The Tower of Babel of liver metastases from colorectal cancer: are we ready for one language?
    Alessandro Bittoni
    Scuola di Specializzazione in Oncologia, Universita Politecnica delle Marche, Via Tronto 10 A, 60100 Ancona, Italy
    Crit Rev Oncol Hematol 85:332-41. 2013
    ..Then we identify three main categories of CRCLM patients, providing clinical recommendations for each...
  34. doi request reprint Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options
    Luca Faloppi
    Scuola di Specializzazione in Oncologia, Universita Politecnica delle Marche, Via Conca, Ancona, Italy
    Cancer Treat Rev 37:169-77. 2011
    ..Only recently the molecular targeted drug, Sorafenib, has been introduced among the therapeutic options for these patients...
  35. ncbi request reprint Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy
    Rossana Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Unmberto 1, G M Lancisi, G Salesi, Ancona, Italy
    Tumori 91:463-6. 2005
    ..The aim of the present study was to analyze the tolerability and activity of chemotherapy with 5-fluorouracil plus oxaliplatin or CPT-11 in elderly patients with advanced colorectal cancer...
  36. ncbi request reprint Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer
    Mario Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
    Tumori 92:384-8. 2006
    ..We evaluated the activity in terms of time to progression (TTP) of mitomycin C and capecitabine in patients with advanced colorectal cancer who progressed after 2 lines of chemotherapy...
  37. ncbi request reprint Angiogenetic pathway as a therapeutic target in renal cell carcinoma
    Maristella Bianconi
    Medical Oncology Clinic, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy
    Anal Quant Cytol Histol 34:15-22. 2012
    ....
  38. doi request reprint Pancreatic cancer: progress in cancer therapy
    Chiara Pierantoni
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi, Ancona, Italy
    Crit Rev Oncol Hematol 67:27-38. 2008
    ..New treatment strategies and a more careful evaluation of innovative therapies are clearly needed for this disease. In this review we will focus on treatment strategies both in resectable and advanced pancreatic cancer...
  39. ncbi request reprint Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
    Stefano Cascinu
    Polytechnic University of Marche Riuniti Hospital Umberto I GM Lancisi G Salesi of Ancona, 60020 Ancona, Italy
    Lancet Oncol 9:39-44. 2008
    ..The aim of this study was to assess the activity and feasibility of a combination of cetuximab with gemcitabine and cisplatin compared with use of gemcitabine and cisplatin alone for the treatment of advanced pancreatic cancer...
  40. pmc Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients
    Riccardo Giampieri
    Department of Medical Oncology, AO Ospedali Riuniti UNIVPM, Ancona, Italy
    PLoS ONE 8:e72843. 2013
    ..This analysis supports the idea that, other than stage, biological variables, such as expression levels of colon cancer stem cell genes, may be relevant in determining an increased risk of relapse in resected colorectal cancer patients...
  41. doi request reprint Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity
    Nicola Battelli
    Clinica di Oncologia Medica, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Italy
    Tumori 97:449-53. 2011
    ..The combination of capecitabine and vinorelbine is a valuable regimen in metastatic breast cancer treatment, even in pretreated patients...
  42. ncbi request reprint Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches
    Mario Scartozzi
    Clinica di Oncologia Medica, Università Politecnica delle Marche Azienda Ospedaliera Umberto I, Ancona, Italy
    Cancer Treat Rev 30:451-9. 2004
    ..e., thymidilate synthase that is targeted by 5FU) or to a new class of antineoplastic molecules (i.e., c-erb B-2 targeted by trastuzumab, COX-2 by NSAIDs, matrix metalloproteinases, EGFR and VEGFR by specific inhibitors)...
  43. ncbi request reprint Epidermal growth factor receptor status in stages of resected non-small cell lung cancer: implications for treatment with epidermal growth factor receptor inhibitors
    Rossana Berardi
    Department of Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero Universitaria, Ospedali Riuniti Umberto I GM Lancisi and G Salesi, Ancona, Italy
    Anal Quant Cytol Histol 33:196-204. 2011
    ..To verify whether epidermal growth factor receptor (EGFR) status could be considered a prognostic factor and assessment of it an effective tool for planning therapy in patients with non-small cell lung cancer (NSCLC)...
  44. ncbi request reprint Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice
    Mario Scartozzi
    Azienda Ospedaliera Ospedali Riuniti Universita, Clinica di Oncologia Medica, Politecnica delle Marche, Via Conca 60020, Ancona, Italy
    Expert Opin Ther Targets 10:281-7. 2006
    ..Moreover, the biological selection of colorectal tumours most likely to benefit from this treatment approach is still to be defined...
  45. ncbi request reprint Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review
    Rossana Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi di Ancona, Via Conca 71, 60020 Ancona, Italy
    Cancer Treat Rev 32:333-47. 2006
    ..In the second part we analysed the new molecular targets developing an hypothesis about the future therapeutics perspectives...
  46. ncbi request reprint Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literature
    Rossana Berardi
    Medical Oncology Department, University of Ancona, Azienda Ospedaliera Umberto I, Ancona, Italy
    Suppl Tumori 2:S45-7. 2003
    ..The aim of the present review is to summarize the results of previously performed randomized trials to evaluate the effects of adjuvant therapy in gastric cancer...
  47. ncbi request reprint Chemotherapy for advanced gastric cancer: across the years for a standard of care
    Mario Scartozzi
    Universita Politecnica delle Marche, Department of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
    Expert Opin Pharmacother 8:797-808. 2007
    ..The objective of this article is to review the present literature available on major Phase II - III clinical trials, in which patients suffering from advanced gastric cancer were treated with cytotoxic chemotherapy...
  48. ncbi request reprint VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
    Mario Scartozzi
    Department of Medical Oncology Translational Oncology Unit AOU Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
    Int J Cancer 135:1247-56. 2014
    ....
  49. ncbi request reprint Gastric cancer treatment: a systematic review
    Rossana Berardi
    Clinica di Oncologia Medica, Università Politecnica delle Marche Azienda Ospedaliera Umberto I, 60020 Ancona, Italy
    Oncol Rep 11:911-6. 2004
    ..This review will focus on the several treatment modalities available for gastric cancer patients: surgery, adjuvant, neoadjuvant and palliative chemotherapy as well as new target agents...
  50. ncbi request reprint The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
    Luca Faloppi
    Department of Medical Oncology, Translational Oncology Unit, AOU Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca 71, 60126 Ancona, Italy
    BMC Cancer 14:110. 2014
    ..Aim of our analysis was to evaluate the role of LDH pre-treatment levels and its variation during treatment in HCC patients receiving sorafenib...
  51. ncbi request reprint New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols
    Rossana Berardi
    Medical Oncology Unit of the Università Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi and G Salesi di Ancona, Ancona, Italy
    JOP 6:118-21. 2005
  52. pmc Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
    Rossana Berardi
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Italy
    Core Evid 5:61-76. 2010
    ..The purpose of this review was to evaluate the patient-related, disease-related and economic-related evidence for the use of panitumumab in the treatment of metastatic colorectal cancer in clinical practice...
  53. ncbi request reprint The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment
    Marco D'Anzeo
    Department of Medical Oncology, Universita Politecnica delle Marche, A O U Ospedali Riuniti Via Conca 71, 60126 Ancona, Italy
    Molecules 19:6393-406. 2014
    ..In this review we summarize the latest findings of miRNAs regulation in HCC and their role as potentially diagnostic and prognostic biomarkers for HCC. We highlight development of miRNAs as potential therapeutic targets for HCC. ..
  54. ncbi request reprint [Non-small cell lung carcinoma: pathology, biology and prognosis]
    Federica Freddari
    Clinica di Oncologia Medica, Universita Politecnica delle Marche, Ancona
    Suppl Tumori 3:S3-4. 2004
  55. ncbi request reprint Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression
    Mario Scartozzi
    Department of Clinica di Oncologia Medica, University of Ancona, Ancona, Italy
    J Clin Oncol 20:1203-8. 2002
    ....
  56. doi request reprint The response of breast cancer cells to mesenchymal stem cells: a possible role of inflammation by breast implants
    Monia Orciani
    Ancona, Italy From the Departments of Clinical and Molecular Sciences Histology and Experimental and Clinical Medicine Clinic of Plastic and Reconstructive Surgery, Università Politecnica delle Marche and the Clinic of Medical Oncology, AO Ospedali Riuniti Università Politecnica delle Marche
    Plast Reconstr Surg 132:899e-910e. 2013
    ..Mesenchymal stem cells can be recruited to sites of inflammation, and their role in cancer development is debated. The authors assessed the effects of inflammation caused by breast implants' effects on tumor...
  57. doi request reprint Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study
    Monica Amati
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Via Tronto 10 A, Torrette di Ancona, Ancona, Italy
    Cancer Epidemiol Biomarkers Prev 17:163-70. 2008
    ..The combination of blood biomarkers and radiographic findings could be used to stratify the risk of mesothelioma in asbestos-exposed populations...